Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

Journal of Experimental Medicine

Volumn 211, Issue 10, 2014, Pages 2061-2074

  Shingai, Masashi ^a   Donau, Olivia K ^a   Plishka, Ronald J ^a   Buckler White, Alicia ^a   Mascola, John R ^a   Nabel, Gary J ^a,k   Nason, Martha C ^a   Montefiori, David ^b   Moldt, Brian ^c   Poignard, Pascal ^c   Diskin, Ron ^d   Bjorkman, Pamela J ^e,f   Eckhaus, Michael A ^g   Klein, Florian ^h   Mouquet, Hugo ⁱ   Lorenzi, Julio Cesar Cetrulo ^h   Gazumyan, Anna ^h   Burton, Dennis R ^c,j   Nussenzweig, Michel C ^f,h   Martin, Malcolm A ^a   Nishimura, Yoshiaki ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h ROCKEFELLER UNIVERSITY   (United States)

ⁱ INSTITUT PASTEUR   (France)

^j MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^k SANOFI   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG BLOOD LEVEL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MACACA; NONHUMAN; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN HUMAN IMMUNODEFICIENCY CHIMERIC VIRUS; SIMIAN HUMAN IMMUNODEFICIENCY CHIMERIC VIRUS INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS; ANIMAL; GENETICS; HUMAN; IMMUNOLOGY; LENTIVIRUS INFECTION; METHODOLOGY; MUTAGENESIS; REGRESSION ANALYSIS; RHESUS MONKEY; SERODIAGNOSIS; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; DNA PRIMERS; HIV; HIV ANTIBODIES; HUMANS; LENTIVIRUS INFECTIONS; MACACA MULATTA; MUTAGENESIS; NEUTRALIZATION TESTS; REGRESSION ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

EID: 84907212727     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20132494     Document Type: Article

References (62)

1. Abela, I.A., L. Berlinger, M. Schanz, L. Reynell, H.F. Gu¨nthard, P. Rusert, and A. Trkola. 2012. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 8:e1002634. http://dx.doi.org/10.1371/journal.ppat.1002634
2. Advisory Committee on Immunization Practices (ACIP), A.E. Fiore, A. Wasley, and B.P. Bell. 2006. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55:1-23.
3. Amanna, I.J., and M.K. Slifka. 2011. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology. 411:206-215. http://dx.doi.org/10.1016/j.virol.2010.12.016
4. Baba, T.W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L.A. Cavacini, M.R. Posner, H. Katinger, G. Stiegler, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206. http://dx.doi.org/10.1038/72309
5. Barnett, S.W., I.K. Srivastava, E. Kan, F. Zhou, A. Goodsell, A.D. Cristillo, M.G. Ferrai, D.E. Weiss, N.L. Letvin, D. Montefiori, et al. 2008. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS. 22:339-348. http://dx.doi.org/10.1097/QAD.0b013e3282f3ca57
6. Barnett, S.W., B. Burke, Y. Sun, E. Kan, H. Legg, Y. Lian, K. Bost, F. Zhou, A. Goodsell, J. Zur Megede, et al. 2010. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 84:5975-5985. http://dx.doi.org/10.1128/JVI.02533-09
7. Barouch, D.H., K.E. Stephenson, E.N. Borducchi, K. Smith, K. Stanley, A.G. McNally, J. Liu, P. Abbink, L.F. Maxfield, M.S. Seaman, et al. 2013a. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 155:531-539. http://dx.doi.org/10.1016/j.cell.2013.09.061
8. Barouch, D.H., J.B. Whitney, B. Moldt, F. Klein, T.Y. Oliveira, J. Liu, K.E. Stephenson, H.W. Chang, K. Shekhar, S. Gupta, et al. 2013b. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 503:224-228.
9. Bogers, W.M., D. Davis, I. Baak, E. Kan, S. Hofman, Y. Sun, D. Mortier, Y. Lian, H. Oostermeijer, Z. Fagrouch, et al. 2008. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology. 382:217-225. http://dx.doi.org/10.1016/j.virol.2008.09.016
10. Buchwald, U.K., and L. Pirofski. 2003. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr. Pharm. Des. 9:945-968. http://dx.doi.org/ 10.2174/1381612033455189
11. Burton, D.R., P. Poignard, R.L. Stanfield, and I.A. Wilson. 2012. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 337:183-186. http://dx.doi.org/10.1126/science.1225416
12. Committee. 1985. Guide for the care and use of laboratory animals. In Department of Health and Human Services publication no. NIH 85-23. National Institutes of Health, Bethesda, MD.
13. Correia, B.E., J.T. Bates, R.J. Loomis, G. Baneyx, C. Carrico, J.G. Jardine, P. Rupert, C. Correnti, O. Kalyuzhniy, V. Vittal, et al. 2014. Proof of principle for epitope-focused vaccine design. Nature. 507:201-206. http://dx.doi.org/10.1038/nature12966
14. Diskin, R., J.F. Scheid, P.M. Marcovecchio, A.P. West Jr., F. Klein, H. Gao, P.N. Gnanapragasam, A. Abadir, M.S. Seaman, M.C. Nussenzweig, and P.J. Bjorkman. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 334:1289-1293. http://dx.doi.org/10.1126/science.1213782
15. Diskin, R., F. Klein, J.A. Horwitz, A. Halper-Stromberg, D.N. Sather, P.M. Marcovecchio, T. Lee, A.P. West Jr., H. Gao, M.S. Seaman, et al. 2013. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J. Exp. Med. 210:1235-1249. http://dx.doi.org/ 10.1084/jem.20130221
16. Doria-Rose, N.A., C.A. Schramm, J. Gorman, P.L. Moore, J.N. Bhiman, B.J. DeKosky, M.J. Ernandes, I.S. Georgiev, H.J. Kim, M. Pancera, et al. NISC Comparative Sequencing Program. 2014. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 509:55-62. http://dx.doi.org/10.1038/nature13036
17. Dreja, H., E. O'Sullivan, C. Pade, K.M. Greene, H. Gao, K. Aubin, J. Hand, A. Isaksen, C. D'Souza, W. Leber, et al. 2010. Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. J. Gen. Virol. 91:2794-2803. http://dx.doi.org/10.1099/vir.0.024224-0
18. Endo, Y., T. Igarashi, Y. Nishimura, C. Buckler, A. Buckler-White, R. Plishka, D.S. Dimitrov, and M.A. Martin. 2000. Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus. J. Virol. 74:6935-6945. http://dx.doi.org/10.1128/JVI.74.15.6935-6945.2000
19. Eugene, H.S., B.R. Pierce-Paul, J.K. Cragio, and T.M. Ross. 2013. Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge. Virol. J. 10:102. http://dx.doi.org/10.1186/1743-422X-10-102
20. Finley, D.J. 2007. Probit Analysis. Cambridge University Press, Cambridge, England. 272 pp.
21. Gautam, R., Y. Nishimura, W.R. Lee, O. Donau, A. Buckler-White, M. Shingai, R. Sadjadpour, S.D. Schmidt, C.C. LaBranche, B.F. Keele, et al. 2012. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J. Virol. 86:8516-8526. http://dx.doi.org/10.1128/JVI.00644-12
22. Hessell, A.J., E.G. Rakasz, D.M. Tehrani, M. Huber, K.L. Weisgrau, G. Landucci, D.N. Forthal, W.C. Koff, P. Poignard, D.I. Watkins, and D.R. Burton. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 84:1302-1313. http://dx.doi.org/10.1128/JVI.01272-09
23. Huang, J., G. Ofek, L. Laub, M.K. Louder, N.A. Doria-Rose, N.S. Longo, H. Imamichi, R.T. Bailer, B. Chakrabarti, S.K. Sharma, et al. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 491:406-412. http://dx.doi.org/10.1038/nature11544
24. Jardine, J., J.P. Julien, S. Menis, T. Ota, O. Kalyuzhniy, A. McGuire, D. Sok, P.S. Huang, S. MacPherson, M. Jones, et al. 2013. Rational HIV immunogen design to target specific germline B cell receptors. Science. 340:711-716. http://dx.doi.org/10.1126/science.1234150
25. Keller, M.A., and E.R. Stiehm. 2000. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13:602-614. http://dx.doi.org/10.1128/CMR.13.4.602-614.2000
26. Klein, F., R. Diskin, J.F. Scheid, C. Gaebler, H. Mouquet, I.S. Georgiev, M. Pancera, T. Zhou, R.B. Incesu, B.Z. Fu, et al. 2013a. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 153:126-138. http://dx.doi.org/10.1016/j.cell.2013.03.018
27. Klein, F., H. Mouquet, P. Dosenovic, J.F. Scheid, L. Scharf, and M.C. Nussenzweig. 2013b. Antibodies in HIV-1 vaccine development and therapy. Science. 341:1199-1204. http://dx.doi.org/10.1126/science.1241144
28. Kong, L., J.H. Lee, K.J. Doores, C.D. Murin, J.P. Julien, R. McBride, Y. Liu, A. Marozsan, A. Cupo, P.J. Klasse, et al. 2013. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20:796-803. http://dx.doi. org/10.1038/nsmb.2594
29. Kozlowski, P.A., R.M. Lynch, R.R. Patterson, S. Cu-Uvin, T.P. Flanigan, and M.R. Neutra. 2000. Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J. Acquir. Immune Defic. Syndr. 24:297-309. http://dx.doi.org/10.1097/ 00126334-200008010-00001
30. Kwong, P.D., and J.R. Mascola. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 37:412-425. http://dx.doi.org/10.1016/j.immuni.2012.08.012
31. Malbec, M., F. Porrot, R. Rua, J. Horwitz, F. Klein, A. Halper-Stromberg, J.F. Scheid, C. Eden, H. Mouquet, M.C. Nussenzweig, and O. Schwartz. 2013. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J. Exp. Med. 210:2813-2821. http://dx.doi.org/10.1084/jem.20131244
32. Mascola, J.R., M.G. Lewis, G. Stiegler, D. Harris, T.C. VanCott, D. Hayes, M.K. Louder, C.R. Brown, C.V. Sapan, S.S. Frankel, et al. 1999. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
33. McLellan, J.S., M. Pancera, C. Carrico, J. Gorman, J.P. Julien, R. Khayat, R. Louder, R. Pejchal, M. Sastry, K. Dai, et al. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 480:336-343. http://dx.doi.org/10.1038/nature10696
34. Moldt, B., E.G. Rakasz, N. Schultz, P.Y. Chan-Hui, K. Swiderek, K.L. Weisgrau, S.M. Piaskowski, Z. Bergman, D.I. Watkins, P. Poignard, and D.R. Burton. 2012. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA. 109:18921-18925. http:// dx.doi.org/10.1073/pnas.1214785109
35. Mouquet, H., L. Scharf, Z. Euler, Y. Liu, C. Eden, J.F. Scheid, A. Halper- Stromberg, P.N. Gnanapragasam, D.I. Spencer, M.S. Seaman, et al. 2012. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA. 109:E3268-E3277. http:// dx.doi.org/10.1073/pnas.1217207109
36. Nishimura, Y., T. Igarashi, N. Haigwood, R. Sadjadpour, R.J. Plishka, A. Buckler-White, R. Shibata, and M.A. Martin. 2002. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76:2123- 2130. http://dx.doi.org/10.1128/jvi.76.5.2123-2130.2002
37. Nishimura, Y., M. Shingai, R. Willey, R. Sadjadpour, W.R. Lee, C.R. Brown, J.M. Brenchley, A. Buckler-White, R. Petros, M. Eckhaus, et al. 2010. Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J. Virol. 84:4769-4781. http://dx.doi.org/10.1128/JVI.02279-09
38. O'Doherty, U., W.J. Swiggard, and M.H. Malim. 2000. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74:10074-10080. http://dx.doi.org/10.1128/JVI.74.21.10074-10080.2000
39. Page, M., R. Stebbings, N. Berry, R. Hull, D. Ferguson, L. Davis, L. Duffy, W. Elsley, J. Hall, C. Ham, et al. 2012. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model. Retrovirology. 9:56. http://dx.doi.org/10.1186/1742-4690-9-56
40. Parren, P.W., P.A. Marx, A.J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J.P. Moore, and D.R. Burton. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75: 8340-8347. http://dx.doi.org/10.1128/JVI.75.17.8340-8347.2001
41. Patel, P, C.B. Borkowf, J.T. Brooks, A. Lasry, A. Lansky, and J. Mermin. 2014. Estimating per-act HIV transmission risk: a systematic review. AIDS. 28:1509-1519.
42. Reed, L.J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
43. Sadjadpour, R., T.S. Theodore, T. Igarashi, O.K. Donau, R.J. Plishka, A. Buckler-White, and M.A. Martin. 2004. Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic. J. Virol. 78:5513-5519. http://dx.doi.org/10.1128/JVI.78.10.5513-5519.2004
44. Scheid, J.F., H. Mouquet, N. Feldhahn, M.S. Seaman, K. Velinzon, J. Pietzsch, R.G. Ott, R.M. Anthony, H. Zebroski, A. Hurley, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIVinfected individuals. Nature. 458:636-640. http://dx.doi.org/10.1038/ nature07930
45. Scheid, J.F., H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 333:1633-1637. http://dx.doi.org/10.1126/ science.1207227
46. Seaman, M.S., H. Janes, N. Hawkins, L.E. Grandpre, C. Devoy, A. Giri, R.T. Coffey, L. Harris, B. Wood, M.G. Daniels, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84:1439-1452. http://dx.doi.org/10.1128/JVI.02108-09
47. Shibata, R., T. Igarashi, N. Haigwood, A. Buckler-White, R. Ogert, W. Ross, R. Willey, M.W. Cho, and M.A. Martin. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:204-210. http://dx.doi.org/10.1038/5568
48. Shingai, M., O.K. Donau, S.D. Schmidt, R. Gautam, R.J. Plishka, A. Buckler- White, R. Sadjadpour, W.R. Lee, C.C. LaBranche, D.C. Montefiori, et al. 2012. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc. Natl. Acad. Sci. USA. 109:19769-19774. http:// dx.doi.org/10.1073/pnas.1217443109
49. Shingai, M., Y. Nishimura, F. Klein, H. Mouquet, O.K. Donau, R. Plishka, A. Buckler-White, M. Seaman, M. Piatak Jr., J.D. Lifson, et al. 2013. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature. 503:277-280.
50. Shu, Y., S. Winfrey, Z.Y. Yang, L. Xu, S.S. Rao, I. Srivastava, S.W. Barnett, G.J. Nabel, and J.R. Mascola. 2007. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine. 25:1398-1408. http://dx.doi.org/10.1016/ j.vaccine.2006.10.046
51. Simek, M.D., W. Rida, F.H. Priddy, P. Pung, E. Carrow, D.S. Laufer, J.K. Lehrman, M. Boaz, T. Tarragona-Fiol, G. Miiro, et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348. http://dx.doi.org/10.1128/JVI.00110-09
52. Sundling, C., M.N. Forsell, S. O'Dell, Y. Feng, B. Chakrabarti, S.S. Rao, K. Lore´, J.R. Mascola, R.T. Wyatt, I. Douagi, and G.B. Karlsson Hedestam. 2010a. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J. Exp. Med. 207:2003-2017. http://dx.doi.org/10.1084/jem.20100025
53. Sundling, C., S. O'Dell, I. Douagi, M.N. Forsell, A. Mo¨rner, K. Lore´, J.R. Mascola, R.T. Wyatt, and G.B. Karlsson Hedestam. 2010b. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus. J. Virol. 84:9086-9095. http://dx.doi.org/10.1128/JVI.01015-10
54. Walker, L.M., S.K. Phogat, P.Y. Chan-Hui, D. Wagner, P. Phung, J.L. Goss, T. Wrin, M.D. Simek, S. Fling, J.L. Mitcham, et al. Protocol G Principal Investigators. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 326:285-289. http://dx.doi.org/10.1126/science.1178746
55. Walker, L.M., M.D. Simek, F. Priddy, J.S. Gach, D. Wagner, M.B. Zwick, S.K. Phogat, P. Poignard, and D.R. Burton. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:e1001028. http:// dx.doi.org/10.1371/journal.ppat.1001028
56. Walker, L.M., M. Huber, K.J. Doores, E. Falkowska, R. Pejchal, J.P. Julien, S.K. Wang, A. Ramos, P.Y. Chan-Hui, M. Moyle, et al. Protocol G Principal Investigators. 2011a. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 477:466-470. http://dx.doi.org/10.1038/nature10373
57. Walker, L.M., D. Sok, Y. Nishimura, O. Donau, R. Sadjadpour, R. Gautam, M. Shingai, R. Pejchal, A. Ramos, M.D. Simek, et al. 2011b. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl. Acad. Sci. USA. 108:20125-20129. http://dx.doi.org/10.1073/pnas.1117531108
58. Willey, R., M.C. Nason, Y. Nishimura, D.A. Follmann, and M.A. Martin. 2010. Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay. AIDS Res. Hum. Retroviruses. 26:89-98. http://dx.doi.org/10.1089/aid.2009.0144
59. Wu, X., T. Zhou, S. O'Dell, R.T. Wyatt, P.D. Kwong, and J.R. Mascola. 2009. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J. Virol. 83:10892-10907. http://dx.doi.org/10.1128/JVI.01142-09
60. Wu, X., Z.Y. Yang, Y. Li, C.M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, S.D. Schmidt, L. Wu, L. Xu, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 329:856-861. http://dx.doi.org/10.1126/science.1187659
61. Xiao, X., W. Chen, Y. Feng, Z. Zhu, P. Prabakaran, Y. Wang, M.Y. Zhang, N.S. Longo, and D.S. Dimitrov. 2009. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390:404-409. http://dx.doi.org/10.1016/j.bbrc.2009.09.029
62. Zhou, T., I. Georgiev, X. Wu, Z.Y. Yang, K. Dai, A. Finzi, Y.D. Kwon, J.F. Scheid, W. Shi, L. Xu, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 329:811-817. http://dx.doi.org/10.1126/science.1192819